Last updated 17th June, 2026
The following disclaimer applies to all scientific information, pipeline data, and forward-looking statements published on this website. Please read it in conjunction with our Terms of Use and Privacy Policy.
Scientific Information and Pipeline Disclaimer
Informational and Pre-Clinical Nature Only
The scientific metrics, target validations, biological assays, and pipeline stages displayed on this website reflect ongoing research and development initiatives conducted by the Company. All data relates exclusively to pre-clinical, in-vitro, in-vivo, or ex-vivo models unless explicitly labelled otherwise.
Not Medical Advice
The content on this website is for high-level informational, academic, and strategic partnership evaluation purposes only. It does not constitute medical advice, clinical diagnostics, or professional healthcare recommendations. No molecule, compound, or investigative framework described herein has been approved for human consumption or commercial distribution by the Central Drugs Standard Control Organisation (CDSCO) of India, the US FDA, or any other global regulatory authority.
No Warranties or Absolute Guarantees
While the Company uses reasonable efforts to ensure the accuracy and currency of the scientific information provided, all content is provided on an "As Is" and "As Available" basis. The Company makes no representations, warranties, or guarantees — express or implied — that the scientific data is free from analytical error, complete, or adaptable for any specific third-party commercial application.
The Company explicitly disclaims all liability for any direct, indirect, or consequential loss arising from reliance on the data or pipeline graphics displayed here.
Forward-Looking Statements and Safe Harbour Notice
Statement Regarding Fundraises and Future Projections
This website, including our published drug discovery pipeline, contains or may contain certain forward-looking statements concerning the Company's research programs, clinical development timelines, operational milestones, capital raises, strategic investments, regulatory pathways, and anticipated corporate growth.
These statements are inherently speculative and can often be identified by the use of forward-looking terminology such as "anticipate," "believe," "estimate," "expect," "intend," "pipeline," "target," "plan," "project," "will," "potential," or similar expressions.
Inherent Risks in Drug Discovery
Drug discovery and development involve an extraordinarily high degree of systemic risk and scientific uncertainty. Actual operational results, capital efficiencies, and clinical outcomes may differ materially from those projected in our forward-looking disclosures due to various risk factors, including but not limited to:
• Unexpected toxicities, lack of efficacy, or inconsistent pharmacokinetic profiles in preclinical or clinical phases.
• Delays in securing regulatory clearances or investigational new drug (IND) approvals from regulatory bodies.
• Changes in the intellectual property landscape, patent rejections, or litigation risks from competing biopharmaceutical entities.
• Macroeconomic market volatilities affecting venture capital allocation, valuation mechanics, and the final terms of the Series A fundraising round.
No Obligation to Update
All forward-looking disclosures on this website speak only as of the date they are published. The Company assumes no legal obligation, liability, or commitment to publicly update, revise, or recalibrate any forward-looking statements or pipeline milestone projections to reflect subsequent events, changing market parameters, or unexpected scientific developments, except as mandated by applicable securities laws.